Answers are grounded in this paper and cite their sources.
Demonstrates improved tumor targeting and penetration in gastric cancer through combined therapies, suggesting enhanced therapeutic efficacy.
The effect of actively targeting nanomaterials on deep tumor penetration is poor, limiting their efficacy. Increasing drug penetration by improving tumor vascular permeability is a promising solution. Herein, we developed nanoparticles consisting of HER2 monoclonal antibody conjugated to poly( l -glutamic acid)-7-ethyl-10-hydroxycamptothecin (HER2-PLG-SN38) and combined them with the vascular disrupting agent combretastatin A4 phosphate (CA4P) to target HER2-expressing gastric cancer cells of the National Cancer Institute-N87 (NCI-N87) cell line. The nanoparticles were synthesized by using click chemistry. In vitro assays showed that HER2-PLG-SN38 significantly increased tumor cell death compared to IgG-PLG-SN38. The amount of HER2-PLG-SN38 infiltrating from the tumor vasculature into the tumor tissue was increased after CA4P treatment. HER2-PLG-SN38 combined with CA4P achieved a tumor suppression rate of 90.8% in vivo compared to that (70.0%) achieved with HER2-PLG-SN38 alone. Our findings suggest that combining HER2-PLG-SN38 with CA4P enhances tumor targeting and penetration, offering a potential strategy for improving the efficacy of nanomaterial-based cancer therapies. This research inspires further exploration of synergistic approaches to overcome the penetration limitations of nanomedicine in cancer treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: